Azitra (AZTR)

• Market cap: $4.55M
• 1 day: -7.53%
• 5 days: -5.51%
• 1 month: -5.71%
• 3 months: -23.88%
• 6 months: -40.34%
• Year to date: -40.65%
• 1 year: -93.94%
• 5 years: -99.82%
• 10 years: -99.82%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Employees: 12

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

47% more capital invested

Capital invested by funds: $109K [Q4 2024] → $161K (+$51.8K) [Q1 2025]

10% more funds holding

Funds holding: 10 [Q4 2024] → 11 (+1) [Q1 2025]

0.21% more ownership

Funds ownership: 3.35% [Q4 2024] → 3.56% (+0.21%) [Q1 2025]